.png){kind=icon}
.png){kind=icon}
Return
LEI-101 produces broad-spectrum analgesia in preclinical pain models
.png){kind=icon}
PRE
AI
M
A
R
DOI：10.1111/bph.70607.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
A promising method for managing pain without the negative effects on the central nervous system linked to CB1 receptor activation or opioid analgesics is the selective activation of the cannabinoid CB2 receptor. Nevertheless, the pharmacological profiles of the available CB2 agonists vary and in certain instances they depend on endogenous opioid signalling. We investigated the pharmacology of the selective CB2 receptor agonist LEI-101 in vitro and in vivo in rodent pain models.
Keywords:
CB2 receptor
chronic pain
inflammation
neuropathic pain
non-opioid analgesia
Journal
IF:
7.7
Papers:
1.4W
Citations:
3.7W
Organization
Cited Papers